Abstract Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD ( p  < 0.001). Two-year overall survival (OS) and PFS (progression free survival) with MSD were significantly better at 58% compared with 50%, p  ≤ 0.001, and 51% vs 47%, p  = 0.029, with a HD. Relapse at 2 years was lower with a HD 23% than with MSD 29% ( p  = 0.016). Non relapse mortality (NRM) was higher with HD in the first 6 months post-transplant HR 2.59 (1.5–4.48) p  < 0.001 and was also higher at 2 years being 30% for HD and 20% for MSD, p  ≤ 0.001. The incidence of acute GVHD grade II-IV and III–IV at 100 days was comparable for MSD and HD, however, chronic GVHD at 2 years was significantly higher with MSD being 44% vs 32% for HD ( p  < 0.001). After multivariable analysis, OS and primary graft failure were significantly worse for HD particularly before 6 months HR 1.93(1.24–3.0), and HR 3.5(1.5–8.1). The median age of HD 37 (IQR 30–47) years was significantly lower than sibling donors 56 (IQR 49–62 years) p  < 0.001. However, there was no effect on NRM, relapse or PFS. This data set suggests that a MSD donor remains the preferred choice in MDS over a haplo donor. Transplants with haploidentical donors result in satisfactory long-term outcome, justifying it’s use when no better donor is available.